论文部分内容阅读
目的探讨FCR方案治疗慢性淋巴细胞性白血病的临床疗效。方法回顾性分析46例慢性淋巴细胞性白血病患者的临床资料,平均分为两组。观察组23例采用FCR方案治疗,对照组23例采用FC方案治疗,比较两组患者治疗后慢性淋巴细胞性白血病的无进展生存期、总体生存率、完全缓解率及不良反应发生情况。结果观察组治疗后慢性淋巴细胞性白血病的无进展生存期明显长于对照组,总体生存率及完全缓解率高于对照组,两组比较差异有统计学意义(P<0.05),且观察组不良反应发生率与对照组比较差异亦有统计学意义(P<0.05)。结论氟达拉滨联合环磷酰胺和美罗华方案治疗慢性淋巴细胞性白血病疗效较好,可有效延长慢性淋巴细胞性白血病的无进展生存期,降低不良反应发生率,提高总体生存率及完全缓解率,值得临床推广。
Objective To investigate the clinical efficacy of FCR regimen in the treatment of chronic lymphocytic leukemia. Methods The clinical data of 46 patients with chronic lymphocytic leukemia were retrospectively analyzed and divided into two groups on average. In the observation group, 23 cases were treated with FCR regimen and 23 cases in control group were treated with FC regimen. The progression-free survival, overall survival, complete remission rate and adverse reactions of chronic lymphocytic leukemia were compared between the two groups. Results The progression-free survival of patients with chronic lymphocytic leukemia was significantly longer in the observation group than in the control group. The overall survival rate and complete remission rate were higher in the observation group than in the control group, with significant difference between the two groups (P <0.05) The incidence of the reaction was also significantly different from the control group (P <0.05). Conclusion Fludarabine combined with cyclophosphamide and rituximab is effective in treating chronic lymphocytic leukemia, which can effectively prolong the progression-free survival, reduce the incidence of adverse reactions, improve the overall survival rate and complete remission rate of chronic lymphocytic leukemia , It is worth clinical promotion.